Trials / Completed
CompletedNCT02756858
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Anavex Life Sciences Corp. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANAVEX2-73 |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2020-11-01
- Completion
- 2020-11-01
- First posted
- 2016-04-29
- Last updated
- 2021-01-12
Locations
5 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT02756858. Inclusion in this directory is not an endorsement.